RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics.
Our flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization.
At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal Investment Team and our portfolio companies (see Beyond Capital). The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics.
RA Capital offers an Entrepreneur-in-Residence (EIR) program for experienced professionals seeking thought partners and a platform to survey diverse landscapes for disruptive innovations. We also have other models for collaborating with experienced drug hunters (see Translation & Hunting).
We are committed to fostering diversity throughout our ecosystem - at RA, in our portfolio companies, and in the broader biotech community.
“We are proud to provide value well beyond capital.”
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. By continuing, you accept the use of these cookies.
dismiss